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GM-CSF and IL-3 are hematopoietic cytokines that modulate the effector functions of several 
immune cell subsets. In particular, GM-CSF and IL-3 exert a significant control on monocyte 
and macrophage effector functions, as assessed in experimental models of inflammatory and 
autoimmune diseases and in human studies. Here we sought to investigate the mechanisms and 
the extent to which GM-CSF and IL-3 modulate the pro-inflammatory, LPS-mediated, 
activation of human CD14+ monocytes taking into account the new concept of trained immunity 
(i.e. the priming stimulus modulates the response to subsequent stimuli mainly by enhancing 
immune activation status). We demonstrate that GM-CSF and IL-3 priming enhances TNF-α 
production upon subsequent LPS stimulation (short-term model of trained immunity) in a p38- 
and SIRT2-dependent manner without increasing TNF mRNA or primary transcript levels (a 
more direct measure of transcription), thus supporting a post-transcriptional regulation of TNF- 
α in primed monocytes. GM-CSF and IL-3 priming followed by 6 days of resting also results 
in increased TNF-α production upon LPS stimulation (long-term model of trained immunity). 
In this case, however, GM-CSF and IL-3 priming induces a c-Myc-dependent monocyte 
renewal and increase in cell number that is in turn responsible for heightened TNF-α production. 
Overall, our results provide insights to understand the biology of monocytes in health and 
disease conditions in which the hematopoietic cytokines GM-CSF and IL-3 play a role and also 




1.1 Innate immune memory and trained immunity 
 
Every encounter between immune cells and a stimulus leaves a footprint, shaping the originally 
naive immune system, which will progressively learn to differentiate between harmless stimuli 
and potentially pathogenic threats [1]. Immunological memory has been classically described 
for the adaptive immune system, in which naive B and T lymphocytes develop antigen-specific, 
long-lasting memory cells after encountering a new antigen. However, accumulating evidence 
highlight that innate immune cells can learn from previous encounter and alter their function, 
demonstrating that immunological memory is not an exclusive peculiarity of lymphocytes. In 
mammals, cells of the innate immune compartments such as monocytes or natural killer (NK) 
cells, build up an innate memory upon a first challenge (priming) with an insult. Once these 
cells encounter a secondary stimulus, either similar or unrelated to the first insult, their response 
is altered, which could result both in a stronger or attenuated response, especially with regards 
to cytokine production. The overall capacity of innate immune cells to remember and alter their 
responses is referred as innate immune memory [2]. The induction of a non-specific memory, 
resulting in an enhanced immune status and enabling a robust cellular response to re- 
stimulation, is termed “trained immunity” [3]. 
Trained immunity has been reported in several organisms and with a variety of stimuli, 
including toll like receptor (TLR) agonists and cytokines. The in vitro and in vivo experimental 
approaches employed so far consist of either priming followed shortly after (e.g. the next day) 
by activation with the same or a different stimulus (short-term model) [4-9], or priming 
followed by prolonged resting (e.g. 5-6 days or several weeks) before stimulation (long-term 
model) [10-14]. Most of these models point to epigenetic and metabolic reprogramming as 
mechanisms to retain memory of the priming stimulus (Figure 1). Nevertheless, we still lack 
complete knowledge of the mediators and the cellular and molecular mechanisms of trained 
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immunity, as well as the way it could exert long-lasting effects in the organism since the cells 
of the innate immune system have a short lifespan in circulation. 
The answer to these questions is poised to have broad implications for understanding the 
pathogenesis of and defining new therapeutic strategies for infectious and chronic inflammatory 
diseases as well as vaccine design [15-17]. 
 
 
Figure 1. Trained Immunity: an innate immune memory program induced by a variety of stimuli, eg 
BCG, that results in a more active functional state of innate immune cells and confers broad non-specific 





Monocytes are innate immune cells that play distinct roles in tissue homeostasis and immunity. 
Monocytes are functionally characterized by the ability to phagocytose, produce cytokines, and 
present antigen; they are members of the mononuclear phagocyte system, a family of myeloid 
cells that comprises monocytes and two other major subtypes: namely, dendritic cells (DCs) 
and macrophages. Monocytes originate in the bone marrow and continuously enter the blood 
circulation, where they constitute ~10% of the total leukocyte population. Circulating 
monocytes represent a versatile and dynamic cell population, composed of multiple subsets 
which differ in phenotype, size, morphology, and transcriptional profiles [18]. 
In human peripheral blood, three functionally different subsets of monocytes have been 
identified and characterized based on the differential expression of CD14 and CD16 cell surface 
markers (Figure 2). The major monocyte subset, accounting for approximately 90% of the total 
monocyte population, expresses high levels of CD14 and no CD16 (CD14++ CD16-), these cells 
are referred to as classical monocytes. Monocytes expressing CD16 can be further divided into 
two distinct subpopulations: intermediate monocytes (CD14+ CD16+) and non-classical 
monocytes expressing low levels of CD14 (CD14lowCD16++) [19]. 
The non-classical monocyte subset demonstrates patrolling behavior along blood vessel walls. 
Classical and intermediate monocytes, also known as inflammatory monocytes, are rapidly 
recruited to sites of infection [20] and injury [21], where, in response to environmental cues 
and molecular mediators, exhibit considerable functional plasticity [22] and can differentiate 
into monocyte-derived macrophages. Monocyte-derived macrophages are commonly classified 
into “classical” or “pro-inflammatory” (M1) and “alternative” or “anti-inflammatory” (M2) 
macrophages. 
Most of the functional and molecular studies on monocyte and macrophage effector functions 
have relied on the activation of these cells by discrete stimuli, for example by LPS/IFN-γ for 
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M1 polarization, IL-4/IL-13 for M2 polarization [23]. However, it is now clear that monocytes 
and macrophages are exposed to a plethora of stimuli in vivo that eventually determines their 
functional specialization [24]. Moreover, these cells may be exposed to different and sometimes 
opposing stimuli in a sequential manner, and the priming stimulus may exert a significant 
control over the response to subsequent stimuli, leading to an enhanced activation status (trained 
immunity or trained monocytes). Recent studies have also shown that circulating monocytes 
and myeloid progenitor cells in the bone marrow are able to reprogram towards a long-term 
non-specific pro-inflammatory phenotype following initial exposure to microorganisms or 
microbial products [25]. Interestingly, trained immunity is not only induced by microbial 
products, but also by endogenous stimuli, such as cytokines [17;26]. Although beneficial in the 
context of resistance against reinfections, this mechanism might be detrimental in non- 
infectious chronic inflammatory conditions in which myeloid cells contribute to disease 
progression. Therefore, it is necessary to elucidate the mechanisms and the context in which 





Figure 2. Blood monocyte subsets in man. Illustration of the definition of human monocyte subsets in 
health based on a typical distribution of events in a CD14 CD16 staining. From Ziegler-Heitbrock L. 
2015. Front Immunol. 6:423. 
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1.3 GM-CSF and IL-3 
 
Granulocyte–macrophage colony-stimulating factor (GM-CSF) and interleukin-3 (IL-3), are 
members of a small family of cytokines (also including IL-5), that regulates the production and 
activity of hematopoietic cells. 
In contrast to many other cytokines, the biological activities of GM-CSF and IL-3, are largely 
not essential for the maintenance of steady-state functions [27]. Instead, the GM-CSF/IL-3 
family of cytokines plays a key role in emergency hematopoiesis and immune response. They 
are produced by many immune and non immune cells, mainly by activated T cells, following 
infection, and serve to elevate leukocyte numbers and heighten their activation status, in 
particular stimulating the function of myeloid cells. 
GM-CSF and IL-3 bind to heterodimeric cell surface receptors composed of a β common (βc) 
subunit (CD131), which is the principal signal transducing subunit, and a cytokine specific α 
subunits (CD116 and CD123, respectively) [28]. Receptors for the GM–CSF/IL-3 family of 
cytokines are expressed at very low level (< 1,500 receptors per cell) on hematopoietic cells. 
The binding of cytokine to its cognate receptor activates several signaling pathways (Figure 3) 
including: Janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathway, 
the mitogen-activated protein kinase (MAPK) pathway, the phosphatidylinositol 3-kinase (PI3- 
K) pathway and the nuclear factor NF-κB pathway. These pathways collectively regulate cell 
survival, proliferation, and differentiation as well as effector functions of several mature 




Figure 3. The GM-CSF receptor and initiation of signal transduction. From van de Laar, L., Paul 
J. Coffer, P.J., Woltman, M.A. (2012). Blood 119:3383-3393. 
 
 
1.3.1 GM-CSF and IL-3: role in inflammatory and autoimmune diseases 
 
GM-CSF and IL-3 modulate the effector functions of several mature immune cells including 
human and mouse mononuclear phagocytes (i.e. monocytes, macrophages and DCs), thereby 
exerting an important role in maintaining tissue homeostasis as well as in the pathogenesis of 
inflammatory and autoimmune diseases [29-33]. 
For example, GM-CSF deficiency leads to impaired alveolar macrophage differentiation and 
pulmonary alveolar proteinosis. GM-CSF promotes the maturation and effector functions of 
myeloid cells (e.g. monocytes and neutrophils) and plays a protective role in an experimental 
model of acute sepsis [34]. On the contrary, IL-3 exacerbates myelopoiesis and incites a 
cytokine storm (i.e. TNF-α, IL-1β and IL-6) that is detrimental to the host in the same sepsis 
model [35]. In an animal model of multiple sclerosis (experimental autoimmune 
encephalomyelitis) conditional deletion of Csf2rb (the mouse orthologue of CD131) in CCR2+ 
monocytes abrogates a pathogenetic signature that is required for disease development [30]. In 
patients with rheumatoid arthritis, elevated concentrations of GM−CSF and its receptor  have 
been observed in tissue and synovial fluid [36] and recombinant GM−CSF administration 
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exacerbates RA disease activity. Of note, an anti-GM-CSF receptor α monoclonal antibody has 
been shown to reduce disease activity in patients with rheumatoid arthritis [37]. 
We have recently shown that GM-CSF and IL-3 synergize with IL-4 to enhance the production 
of the IL-4-responsive chemokine CCL17/TARC by human CD14+ monocytes [38]. Thus, GM- 
CSF and IL-3 exert a significant control on monocyte effector functions. The mechanisms and 
the extent to which GM-CSF and IL-3 modulate the pro-inflammatory (e.g. LPS-mediated) 
activation of human CD14+ monocytes are still unclear. 
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2. Aim of the study 
 
Monocytes and macrophages are exposed to a plethora of stimuli in vivo that eventually 
determines their functional specialization [24]. Moreover, these cells may be exposed to 
different and sometimes opposing stimuli in a sequential manner, and the priming stimulus may 
exert a significant control over the response to subsequent stimuli. This phenomenon, which is 
referred to as innate immune memory or trained immunity, has been reported in several 
organisms and with a variety of stimuli, including toll-like receptor agonists and cytokines [17]. 
GM-CSF and IL-3 are hematopoietic cytokines produced by many immune and non immune 
cells and are important mediators of emergency myelopoiesis [27]. GM-CSF and IL-3 modulate 
the effector functions of several immune cell subsets and exert a significant control on 
monocyte effector function in inflammatory and autoimmune diseases [29-33]. 
We have recently shown that GM-CSF and IL-3 synergize with IL-4 to enhance the production 
of the IL-4-responsive chemokine CCL17/TARC by human CD14+ monocytes [38]. However, 
the mechanisms and the extent to which GM-CSF and IL-3 modulate the pro-inflammatory 
(e.g. LPS-mediated) activation of human CD14+ monocytes are still unclear. Here we sought 
to investigate whether GM-CSF and IL-3 modulate the pro-inflammatory, LPS-mediated, 
activation of human CD14+ monocytes taking into account the new concept of trained 
immunity. 
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3. Materials and methods 
 
3.1 Cell isolation and culture 
 
The study protocol involving the use of human blood cells was approved by the Ethics 
Committee of the University of Naples Federico II. Cells were isolated from buffy coats of 
healthy donors. Blood was layered onto Histopaque-1077 (Sigma-Aldrich) and mononuclear 
cells were collected at the interface. Monocytes were further purified with anti-CD14 
Microbeads (Miltenyi Biotec). Purity of cell preparations was > 95% as assessed by flow 
cytometry. Cells were cultured in cIMDM-5 (IMDM, 5% FCS, 1x non essential amino acids, 
1x UltraGlutamine, 25 mM HEPES, 5 μg/mL gentamicin [Lonza]) in 96-well flat-bottom plates 
(105 monocytes/well) in a final volume of 250 μL. For experiments involving flow cytometry, 
cells were cultured in suspension (1.5 mL tubes) in cIMDM-5 at a concentration not greater 
than 2*106 cells/mL, then spun down and collected for subsequent experiments. 
Cells were treated with different combinations of: LPS (E. coli 026:B6) 10 ng/mL (Sigma 
Aldrich), IL-3 5 ng/mL (Peprotech), M-CSF 25 ng/mL, GM-CSF 5 ng/mL (Miltenyi Biotec), 
P3CSK4 10 ng/mL, Poly(I:C) 1 µg/mL, flagellin 10 ng/mL, imiquimod 1 µg/mL, ODN2006 1 
µM (Invivogen), BAY11-7082 1 µM, SP600125 2 µM, rapamycin 50 and 250 nM, torin1 10 
 
and 50 nM, AGK2 10 µM, APO866 0.1, 1 and 10 nM, TG101348 125, 250 and 500 nM 
 
(Selleckchem), UO126 2 µM, LY294002 10 µM, SB203580 2 µM (Cell Signaling 
Technology), 10058-F4 40 µM, EX-527 500 nM (Tocris Bioscience), 2-Deoxy-D-Glucose 1 
mM, Etomoxir 40 µM, BAY 85-3934 1 µM, CAY-10585 10 µM (Cayman Chemical), nicotinic 




3.2 ELISA and NAD quantification 
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Cytokine concentrations in cell-free supernatants or total protein lysates (0.1% Triton X-100) 
were measured using ELISA kits for TNF-α (R&D Systems), IL-1β and IL-6 (eBioscience). 
Standard curves were generated with a Four Parametric Logistic curve fit and data were 
analysed using MyAssays Analysis Software Solutions (www.myassays.com). Cytokine levels 
in protein lysates were normalized on total protein concentrations as determined by Bradford 
protein assay (Biorad) and expressed as pg of cytokine/μg of total protein. Intracellular NAD 
levels were measured using the colorimetric assay NAD/NADH Quantitation assay (Sigma 
Aldrich) according to the manufacturer’s protocol and expressed as fold over control. 
 
 
3.3 Phospho-flow cytometry 
 
Monocytes were collected, rested in cIMDM-0.5 (0.5% FCS) for 1 hour and stimulated with 
LPS for the indicated times. Then, cells were fixed with 1.5% paraformaldehyde (EM-grade, 
Electron Microscopy Sciences) and permeabilized with absolute ice-cold methanol. Cells were 
stained (60 minutes at room temperature) in PBS + 10% human AB serum (Lonza) + 0.05% 
NaN3 with the following antibodies: anti-human-phospho-p38 PE (T180/Y182) (3D7, dilution 
1:50), anti-human-phospho-p44/42 (ERK1/2) PE (T202/Y204) (19762, dilution 1:50) (Cell 
Signaling Technology). Samples were acquired on MACSQuant Analyzer 10 (Miltenyi Biotec) 
and analyzed using FlowJo v10. Doublets and debris were excluded from the analysis. Data are 
expressed as percentage of positive cells and median fluorescence intensity (MFI). 
 
 
3.4 Fluorescence, time-lapse and high-content microscopy 
 
Microscopy experiments were performed with the Operetta High-Content Imaging System 
(PerkinElmer). Monocytes were cultured in 96-well black CellCarrier plates (PerkinElmer). For 
fluorescence microscopy, cells were fixed with 1% paraformaldehyde (EM-grade, Electron 
Microscopy Sciences) and permeabilized with PBS + 0.1% Triton X-100. Then, actin was 
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stained with rhodamin phalloidin and nuclei with Hoechst 33342 (ThermoFishcer Scientific) 
according to manufacturer’s protocol. Representative images were taken with a 60x objective. 
For time-lapse microscopy, monocytes were cultured for 6 days at controlled temperature 
(37°C) and CO2 (5%). Over this time window, digital phase contrast images of 15 fields/well 
were taken every 60 minutes with a 20x objective. To quantify cell confluency, brightfield 
images of 15 fields/well were taken on days 1, 4, 7 and 8 with a 20x objective. PhenoLOGIC 
(PerkinElmer) was employed for image segmentation and to calculate the cell-free area (b) 
and the area covered by cells (a). Cell confluency was calculated as a proportion of cell area 
over total cell area using the following formula: (a/(a+b))*100. 
 
 
3.5 RNA isolation and real time RT-PCR 
 
RNA was extracted using TRIzol (ThermoFischer Scientific) and reverse-transcribed (500 ng) 
using SuperScript III Reverse Transcriptase (ThermoFischer Scientific). Real time RT-PCR 
was performed by using Universal SYBR Green Supermix (Bio-Rad) on CFX96 Real Time 
detection system (Bio-Rad). Relative quantification of gene expression was calculated by the 
ΔCt (relative expression x 104) method. Each Ct value was normalized to the respective 
ubiquitin C (UBC) Ct value. The following primer pairs were used: TNF mRNA forward 5’- 
tctccttcctgatcgtggca-3’; TNF mRNA reverse 5’-cagcttgagggtttgctacaac-3’; TNF primary 
transcript forward 5’-taagggtgactccctcgatgt-3’; TNF primary transcript reverse 5’- 
ccaaacccaaacccagaatta-3’; SIRT2 forward 5’-cccaaccccagcaaatctctaa-3’; SIRT2 reverse 5’- 
ggctggtagagatgcctgtt-3’; MYC forward 5’-attctctgctctcctcgacg-3’; MYC reverse 5’- 
agcctgcctcttttccaca-3’; MAFB forward 5’-gtatgaaccgcatggtgcttg-3’; MAFB reverse 5’- 




3.6 Statistical analysis 
 
Statistical analysis was performed with Prism 6 (GraphPad Software). P values were calculated 




4.1 GM-CSF and IL-3 priming enhances LPS-induced TNF-α production 
 
In order to evaluate the effect of GM-CSF and IL-3 on the pro-inflammatory LPS-mediated 
activation of human CD14+ monocytes, we simultaneously treated these cells with LPS and 
GM-CSF or IL-3, and then assessed the production of TNF-α, IL-1β and IL-6. Surprisingly, 
neither GM-CSF (Figure 4A) nor IL-3 (Figure 4B) modulated cytokine production in response 
to LPS. 
Since several stimuli may act as priming stimuli [17;26], we reasoned that GM-CSF and IL-3 
could prime monocytes for increased responsiveness to LPS. Monocytes were left untreated 
(CTRL) or treated for 18 hours with M-CSF, IL-3 or GM-CSF, washed and then stimulated 
with LPS for additional 16-18 hours (short-term model of trained immunity). Interestingly, 
priming with GM-CSF or IL-3 increased LPS-induced TNF-α production, while IL-1β and IL- 
6 were marginally affected (Figure 5). We also evaluated phagocytic activity of primed 
monocyte, GM-CSF and IL-3 priming did not enhance Escherichia coli phagocytosis. 
To verify whether the priming effect was shared among different TLRs, we stimulated primed 
monocytes with LPS (TLR4 agonist), P3CSK4 (TLR2 agonist), Poly(I:C) (TLR3 agonist), 
flagellin (TLR5 agonist), imiquimod (TLR7 agonist) or ODN 2006 (TLR9 agonist). The 
priming effect was more pronounced when monocytes were stimulated with LPS, although a 
trend toward an increase in TNF-α production was also observed with P3CSK4 (Figure 6). 
Finally, a time-course analysis revealed that at least 3 (for IL-3) or 6 (for GM-CSF) hours of 
priming were required to observe increased TNF-α secretion upon LPS stimulation (Figure 7). 
To gain insights into the molecular mechanisms of monocyte priming, we selectively treated 
monocytes during the priming phase with inhibitors of pathways that are known to modulate 
monocyte and macrophage activation: JAK2 (TG101348), NF-κB (BAY 11-7082), c-Myc 
(10058 F4), HIF-1α (CAY10585), PHD (BAY 85-3934), PI3K (LY294002), MEK1/2 (U0126), 
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p38 (SB203580), JNK (SP600125), hexokinase (2-Deoxy-D-Glucose, inhibitor of glycolysis), 
CPT1 (etomoxir, inhibitor of fatty acid β-oxidation). The readout of these experiments was the 
modulation of TNF-α production by primed monocytes without affecting unprimed cells. Most 
of the inhibitors had no or negligible effects on primed cells, while TG101348 reduced TNF-α 





Figure 4. (A, B) Human CD14+ monocytes were stimulated with LPS and GM-CSF (A) or IL-3 (B) for 
16-18 hours. TNF-α, IL-1β and IL-6 levels were assessed by ELISA in cell-free supernatants. Data are 
shown as mean + SEM of 5 (A) or 6 (B) independent experiments and were analyzed by repeated 














Figure 5. Human CD14+ monocytes were left unprimed (CTRL) or primed with M-CSF, IL-3 and GM- 
CSF for 18 hours (day 1), then washed and left untreated or stimulated with LPS for 16-18 hours (day 
2). TNF-α, IL-1β and IL-6 levels were assessed by ELISA in cell-free supernatants. Data are shown as 
mean + SEM of 7 independent experiments. ** P < .01 determined by repeated measure two-way 





Figure 6. Human CD14+ monocytes were left unprimed (CTRL) or primed with IL-3 for 18 hours (day 
1), then washed and stimulated with several TLR agonists for 16-18 hours (day 2). TNF-α levels were 
assessed by ELISA in cell-free supernatants. Data are shown as mean + SEM of 4 independent 

















Figure 7. Human CD14+ monocytes were primed with IL-3 (left panel) or GM-CSF (right panel) for 
different times as indicated in the figure, then washed and left untreated or stimulated with LPS for 16- 
18 hours (day 2). TNF-α levels were assessed by ELISA in cell-free supernatants. Data are shown as 
mean + SEM of 8 independent experiments. ** P < .01 determined by repeated measure two-way 




Figure 8. Human CD14+ monocytes were primed with IL-3 and the indicated compounds for 18 hours 
(day 1), then washed and left untreated or stimulated with LPS for 16-18 hours (day 2). TNF-α levels 
were assessed by ELISA in cell-free supernatants. Data are shown as mean + SEM of 4-10 independent 
experiments. * P < .05, ** P < .01 determined by repeated measure two-way ANOVA with Tukey’s or 
Sidak’s post hoc test. 
23  
4.2 GM-CSF and IL-3 priming modulate TNF-α production at the post- 
transcriptional level 
To obtain some clue on the modulation of TNF-α in GM-CSF and IL-3 primed monocytes, we 
performed a time-course analysis of TNF-α intracellular protein, mRNA and primary transcript 
levels (which is a more direct measure of transcription and is detected by using intronic PCR 
primers) [39]. GM-CSF and IL-3 priming resulted in the highest TNF-α intracellular protein 
levels as early as after 1 hour of LPS stimulation (Figure 9A). After 4 hours of LPS stimulation 
TNF-α intracellular protein levels were even more increased in primed monocytes (Figure 9B). 
The same pattern of TNF-α production was observed in cell-free supernatants. Unexpectedly, 
TNF mRNA (Figure 10A) and primary transcript (Figure 11A) levels were either not modified 
or only slightly increased by GM-CSF and IL-3 priming after 1 hour of LPS stimulation. After 
4 hours, IL-3 priming increased TNF mRNA levels (Figure 10B) whereas TNF primary 
transcript levels were unchanged compared to unprimed cells (Figure 11B), suggesting that IL- 
3 priming increases TNF mRNA stability. Thus, GM-CSF and IL-3 priming uncouples TNF-α 
protein and primary transcript levels upon LPS stimulation, thereby suggesting that TNF-α 






Figure 9. (A-B) Human CD14+ monocytes were primed with GM-CSF and IL-3 for 18 hours (day 1), 
then washed and stimulated with LPS (day 2) for 1 (A) or 4 (B) hours. TNF-α protein abundance (A, B) 
was measured in protein lysates by ELISA. Data are shown as the median, the 25th and 75th percentiles 
(boxes) and the 5th and 95th percentiles (whiskers) of 8 independent experiments. * P < .05, ** P < .01 




Figure 10. (A-B) Human CD14+ monocytes were primed with GM-CSF and IL-3 for 18 hours (day 1), 
then washed and stimulated with LPS (day 2) for 1 (A) or 4 (B) hours. TNF mRNA measured by real 
time RT-PCR. Data are shown as the median, the 25th and 75th percentiles (boxes) and the 5th and 95th 
percentiles (whiskers) of 8 independent experiments. * P < .05, ** P < .01 determined by Friedman 




Figure 11. (A-B) Human CD14+ monocytes were primed with GM-CSF and IL-3 for 18 hours (day 1), 
then washed and stimulated with LPS (day 2) for 1 (A) or 4 (B) hours. TNF primary transcript was 
measured by real time RT-PCR. Data are shown as the median, the 25th and 75th percentiles (boxes) and 
the 5th and 95th percentiles (whiskers) of 8 independent experiments. * P < .05, ** P < .01 determined 
by Friedman test with Dunn’s post hoc test. 
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4.3 NAD-dependent SIRT2 and MAPKs ERK1/2 and p38 mediate the effect of GM- 
CSF and IL-3 priming on TNF-α production 
The expression of several genes with immune function (including TNF-α) can be regulated at 
the translational level, thereby modulating protein abundance independently of de novo 
transcription [40-42]. A central (albeit not exclusive) role in the modulation of mRNA 
translation is played by the translation-initiation factor eIF4E, whose activity is regulated by 
mTORC1 (a multiprotein complex that includes the serine/threonine kinase mTOR and raptor) 
and the MAPKs ERK1/2 and p38 [41]. 
TNF-α protein levels are also regulated by metabolic cues. Depletion of the intracellular pool 
of nicotinamide adenine dinucleotide (NAD) by the nicotinamide phosphoribosyltransferase 
(Nampt) inhibitor APO866 inhibits TNF-α protein production in response to LPS without 
modifying TNF mRNA levels. The effect of APO866 is reverted by the addition of nicotinic 
acid (NA, a substrate for Nampt-independent NAD synthesis), and is mimicked by inhibitors 
of the NAD-dependent histone deacetylases sirtuin (SIRT) 1 and 2 [43;44]. Thus, we reasoned 
that these pathways could contribute to the modulation of TNF-α protein levels in GM-CSF and 
IL-3 primed cells and proceeded to investigate this hypothesis. 
First, we assessed the contribution of mTORC1 by employing 2 different mTOR inhibitors 
(rapamycin and torin 1) and also an inhibitor of SIRT2 (which is involved in the regulation of 
the mTOR-activated translational machinery) [45]. We added the inhibitors along with LPS and 
evaluated TNF-α intracellular protein levels after 1 hour of stimulations. None of these 
inhibitors modulated TNF-α production in both unprimed and primed monocytes (Figure 12). 
Then, we employed the same approach using inhibitors of MAPKs (i.e. ERK1/2, p38, JNK). 
The p38 inhibitor SB203580 reduced TNF-α intracellular protein in both unprimed and GM- 
CSF or IL-3 primed cells (Figure 13A), while ERK1/2 inhibition with the MEK1/2 inhibitor 
U0126 was effective only in GM-CSF primed cells (Figure 14A). No effect for the JNK 
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inhibitor SP600125 could be observed (data not shown). Importantly, p38 (Figures 13B, C) and 
ERK1/2 inhibition (Figures 14B, C) did not significantly modulate TNF RNA levels. 
As early as after 15 minutes of stimulation GM-CSF and IL-3 primed cells exhibited the highest 
phosphorylation of p38, as assessed by the percentage (compared to unprimed cells) and the 
median fluorescence intensity (compared to M-CSF primed cells) of phospho-p38+ cells (Figure 
15A). On the contrary, only GM-CSF primed cells exhibited increased ERK1/2 
phosphorylation compared to unprimed or M-CSF primed cells (Figure 15B). 
TNF-α production can also be regulated by metabolic cue, we used APO866 and NA to evaluate 
whether intracellular NAD levels contributed to the priming effect of GM-CSF and IL-3. We 
found that APO866 inhibited TNF-α secretion only when administered during priming (Figure 
16A), moreover in a dose dependent manner. Importantly, the addition of NA reverted the effect 
of APO866 (Figure 16B). 
We verified that APO866 reduced while NA addition restored intracellular NAD levels (Figure 
17A). Interestingly, GM-CSF and IL-3 priming increased intracellular NAD levels compared 
to unprimed cells. However, the same effect was observed with M-CSF priming (Figure 17B), 
which does not modulate TNF-α secretion. Thus, the increase in intracellular NAD levels is a 
condition required but not sufficient for the priming effect of GM-CSF and IL-3. 
We then evaluated the involvement of the NAD-dependent histone deacetylases SIRT1 and 
SIRT2 in GM-CSF and IL-3 priming by using the specific inhibitors EX-527 and AGK2, 
respectively (Figures 18A-B). 
SIRT2 inhibition during priming selectively reduced TNF-α secretion and intracellular protein 
levels (Figure 19A) without significantly modulating TNF RNA (Figures 19B-C), although the 
effect was more pronounced for IL-3 rather than GM-CSF primed cells. We confirmed the 
specificity of SIRT2 involvement by showing that the inhibitor of NAD-independent histone 




Figure 12. Human CD14+ monocytes were primed with IL-3 and the indicated compounds for 18 hours 
(day 1), then washed and left untreated or stimulated with LPS for 1 hour (day 2). TNF-α levels were 
assessed by ELISA in total protein lysates. Data are shown as mean + SEM of 4 independent 




Figure 13. (A-B-C) Human CD14+ monocytes were primed with GM-CSF and IL-3 for 18 hours (day 
1), then washed and left untreated or stimulated with LPS for 1 hour in the presence or in the absence 
of the p38 inhibitor SB203580 (day 2). TNF-α levels were assessed by ELISA in total protein lysates 
(A). Alternatively, cells were harvested for RNA extraction and evaluation of mRNA (B) and TNF 
primary transcript (C) levels by real time RT-PCR. Data are shown as mean + SEM of 4 (A) or 6 (B-C) 
independent experiments. * P < .05, ** P < .01 determined by repeated measure two-way ANOVA with 





Figure 14. (A-F) Human CD14+ monocytes were primed with GM-CSF and IL-3 for 18 hours (day 1), 
then washed and left untreated or stimulated with LPS for 1 hour in the presence or in the absence of 
the MEK1/2 inhibitor U0126 (day 2). TNF-α levels were assessed by ELISA in total protein lysates (A). 
Alternatively, cells were harvested for RNA extraction and evaluation of mRNA (B) and TNF primary 
transcript (C) levels by real time RT-PCR. Data are shown as mean + SEM of 4 (A) or 6 (B-C) 
independent experiments. * P < .05, ** P < .01 determined by repeated measure two-way ANOVA with 
Sidak’s post hoc test. 
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Figure 15. (A, B) Human CD14+ monocytes were left unprimed (CTRL) or primed with M-CSF, IL-3 
and GM-CSF for 18 hours (day 1), then washed and left untreated (0 min) or stimulated with LPS for 
different time points (15 min, 30 min, 60 min). (A) p38 phosphorylation was assessed by flow cytometry 
as percentage (left panel) and MFI (right panel) of phospho-p38+ cells. (B) ERK1/2 phosphorylation 
was assessed by flow cytometry as MFI. (C) Representative histograms of p38 and ERK1/2 
phosphorylation. Data are shown as mean + SEM of 8 independent experiments. * P < .05, ** P < .01 
determined by repeated measure two-way ANOVA with Tukey’s post hoc test. 
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Figure 16. (A) Human CD14+ monocytes were primed with IL-3 in the presence (left panel) or absence 
(right panel) of the Nampt inhibitor APO866 for 18 hours (day 1), then washed and stimulated with LPS 
in the absence (left panel) or presence (right panel) of APO866 for 16-18 hours (day 2). TNF-α levels 
were assessed by ELISA in cell-free supernatants. (B) Cells were stimulated with GM-CSF or IL-3 in 
the presence of APO866 and nicotinic acid (NA) for 18 hours (day1), then washed and stimulated with 
LPS for 16-18 hours (day 2). Data are shown as mean + SEM of 6 independent experiments. * P < .05, 
** P < .01 determined by repeated measure two-way ANOVA with Tukey’s or Sidak’s post hoc test (A, 
respectively left and right panel) or repeated measure one-way ANOVA with Tukey’s post hoc test (B). 
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Figure 17. Human CD14+ monocytes were left untreated (CTRL), stimulated with IL-3 in the presence 
of APO866 and nicotinic acid (NA) (A), or with M-CSF, IL-3 and GM-CSF (B) for 18 hours. 
Intracellular NAD levels were measured in cellular lysates and expressed as fold over CTRL (A, B). 
Data are shown as mean + SEM of 6 independent experiments. * P < .05, ** P < .01 determined by 
repeated measure one-way ANOVA with Tukey’s post hoc test. 
 
Figure 18. Human CD14+ monocytes were primed with GM-CSF and IL-3 for 18 hours in the presence 
of SIRT1 inhibitor EX-527 (A) or SIRT2 inhibitor AGK2 (B) (day 1), then washed and stimulated with 
LPS for 16-18 hours (day 2). TNF-α levels were assessed by ELISA in cell-free supernatants. Data are 
shown as mean + SEM of 7 independent experiments. ** P < .01 determined by repeated measure two- 




Figure 19. (A-C) Human CD14+ monocytes were primed with GM-CSF and IL-3 for 18 hours in the 
presence or absence of the SIRT2 inhibitor AGK2 (day 1), then washed and left untreated or stimulated 
with LPS for 1 hour (day 2). TNF-α levels were assessed by ELISA in total protein lysates (A). 
Alternatively, cells were harvested for RNA extraction and evaluation of TNF mRNA (B) and primary 
transcript (C) levels by real time RT-PCR. Data are shown as mean + SEM of 4 (A) or 6 (B, C) 
independent experiments. * P < .05, ** P < .01 determined by repeated measure two-way ANOVA with 
Sidak’s post hoc test. 
36  
 
Figure 20. Human CD14+ monocytes were primed with GM-CSF and IL-3 for 18 hours in the presence 
of trichostatin A (TSA), an inhibitor of NAD-independent histone deacetylases (day 1), then washed 
and stimulated with LPS for 16-18 hours (day 2). TNF-α levels were assessed by ELISA in cell-free 
supernatants. Data are shown as mean + SEM of 7 independent experiments. ** P < .01 determined by 
repeated measure two-way ANOVA with Tukey’s (A) or Sidak’s (B-D) post hoc test. 
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4.4 GM-CSF and IL-3 priming modulate monocyte renewal in a c-Myc-dependent 
manner 
The results obtained so far have characterized the role of GM-CSF and IL-3 in a short-term 
model of trained immunity. Since the effects of training can be retained by human monocytes 
for several days even in the absence of the training stimulus (e.g. β-glucan) [10;13], we 
investigated the possible roles of GM-CSF and IL-3 in a long-term model of trained immunity. 
Monocytes were primed with GM-CSF, IL-3, M-CSF and LPS for 16-18 hours, washed out and 
rested in complete medium until day 7 when they were stimulated with LPS. In accordance with 
the results obtained with β-glucan, cells primed with GM-CSF or IL-3 secreted higher levels of 
TNF-α compared to those primed with M-CSF and LPS (Figure 21A). Although these results 
could suggest stable chromatin remodeling events in response to GM-CSF and IL-3 priming 
(similar to what has been demonstrated for β-glucan), we also found that GM-CSF and IL-3 
priming increased total cellular protein content (Figure 21B) and that monocytes primed with 
GM-CSF, IL-3 and M-CSF expressed comparable levels of TNF RNA upon LPS stimulation 
(Figure 21C-D). 
Thus, we reasoned that GM-CSF and IL-3 priming could induce monocyte renewal and increase 
the number of cells, which in turn would result in higher TNF-α secretion upon LPS stimulation. 
We investigated this hypothesis by evaluating the degree of cell confluency (assessed as the 
proportion of cell area to total area). Monocytes primed with GM-CSF and IL-3 reached 
remarkable higher cell confluency on day 7 compared to monocyte primed with M-CSF or LPS 
(Figure 22A). Comparable results were obtained when we expressed cell confluency on days 4, 
7 and 8, as fold increase over day 1, to account for possible differences in cell detachment after 
the washing step (Figure 22B). We also obtained evidence of increased cell number following 
GM-CSF and IL-3 priming by fluorescence (Figure 22C) and time-lapse microscopy. Thus, 
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GM-CSF and IL-3 priming induces monocyte renewal in a long-term model of trained 
immunity. 
Maintenance of the pool of tissue-resident macrophages is supported by self-renewal without 
the contribution of hematopoietic stem cell in several experimental models [46-49]. 
Interestingly, macrophage renewal is sustained by a gene network that includes the transcription 
factor c-Myc and requires downregulation of the transcription factor MafB [50;51]. In keeping 
with these data, GM-CSF and IL-3 priming increased the MYC/MAFB mRNA ratio compared 
to M-CSF priming (Figure 23). Moreover, the c-Myc inhibitor 10058 F4 restrained monocyte 
renewal induced by GM-CSF and IL-3 priming (Figure 24). 
To better characterize the pathways required for GM-CSF- and IL-3-induced monocyte 
renewal, we employed metabolic inhibitors (2-Deoxy-D-Glucose, etomoxir, APO866) and 
inhibitors of the signaling pathway activated upon GM-CSF/IL-3 receptor stimulation. 
Inhibitors were added along with GM-CSF or IL-3 and then cell confluency was evaluated as 
indicated above. Metabolic inhibitors as well the JNK inhibitor SP600125 (Figure 25) had no 
effect on cell confluency. The selective JAK2 inhibitor TG101348 (Figure 26A), the pan-JAK 
inhibitor Pyridone 6 (Figure 26B) and the p38 inhibitor SB203580 (Figure 26C) restrained only 
IL-3 priming-induced monocyte expansion. Finally, the PI3K inhibitor LY294002 (Figure 27A) 
and the MEK1/2 inhibitor U0126 (which in turn inhibits ERK1/2 activity) (Figure 27B) reduced 
monocyte expansion in response to both GM-CSF and IL-3 priming, although IL-3 priming 




Figure 21. Human CD14+ monocytes were primed with IL-3, GM-CSF, M-CSF or LPS for 16-18 hours, 
washed out and rested in complete medium until day 7. On day 7 cells were stimulated with LPS for 16- 
18 hours (A, B, C) or 1 hour (D). TNF-α levels were assessed by ELISA in cell-free supernatants (A). 
Cells were harvested for total protein quantification (B) or RNA extraction and evaluation of TNF 
primary transcript and mRNA levels by real time RT-PCR (C, D). Data are shown as mean + SEM of 
10 (A, B, C) or 5 (D) independent experiments. * P < .05, ** P < .01 determined by repeated measure 




Figure 22. (A-C) Human CD14+ monocytes were primed with IL-3, GM-CSF, M-CSF or LPS for 16- 
18 hours, washed out and rested in complete medium until day 7. On day 7 cells were stimulated with 
LPS for 16-18 hours. Brightfield images (15 fields/well) were obtained at the indicated time points with 
a 20x objective. The percentage of cell area/total area was calculated and expressed as absolute values 
(A) or fold increase over day 1 (B). On day 8 representative fluorescence microscopy images were also 
obtained with a 60x objective. Data are shown as mean + SEM of 8 independent experiments. Orange, 
actin; blue, nuclei (C). ** P < .01 determined by repeated measure two-way (A, B) ANOVA with 
Tukey’s post hoc test. 
 
 
Figure 23. Human CD14+ monocytes were primed with IL-3, M-CSF or GM-CSF for 18 hours. Then, 
cells were harvested for RNA isolation and MYC and MAFB mRNA levels were evaluated by real time 
RT-PCR. Data are shown as mean + SEM of 7 independent experiments. * P < .05, ** P < .01 determined 
by repeated measure one-way (A) ANOVA with Tukey’s post hoc test. 
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Figure 24. Human CD14+ monocytes were primed with IL-3, GM-CSF, M-CSF or LPS for 16-18 
washed out and rested in complete medium until day 7. On day 7 cells were stimulated with LPS for 16- 
18 hours. Cells were also treated with the c-Myc inhibitor 10058 F4 on day 1 (upper panels), day 1 and 
2 (middle panels), day 1, 2 and 4 (lower panels). Analysis was performed as in Fig. 22B. Data are shown 
as mean + SEM of 8 independent experiments. * P < .05, ** P < .01 determined by repeated measure 





Figure 25. Human CD14+ monocytes were primed with GM-CSF (upper panels), IL-3 (lower panels) 
and M-CSF for 16-18, washed out and rested in complete medium until day 7. On day 7 cells were 
stimulated with LPS for 16-18 hours. Cells were also treated with different inhibitors during the priming 
phase. Analysis was performed as in Fig. 22B. Data are shown as mean + SEM of 8 independent 
experiments. Data were analysed by repeated measure two-way ANOVA with Tukey’s post hoc test. 
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Figure 26. (A-C) Human CD14+ monocytes were primed with IL-3, GM-CSF, M-CSF for 16-18 hours, 
washed out and rested in complete medium until day 7. On day 7 cells were stimulated with LPS for 16- 
18 hours. Cells were also treated different inhibitors during the priming phase. Analysis was performed 
as in Fig. 22B. Data are shown as mean + SEM of 8 independent experiments. * P < .05, ** P < .01 





Figure 27. (A-B) Human CD14+ monocytes were primed with IL-3, GM-CSF, M-CSF for 16-18 hours, 
washed out and rested in complete medium until day 7. On day 7 cells were stimulated with LPS for 16- 
18 hours. Cells were also treated with with the PI3K inhibitor LY294002 (A) and the MEK1/2 inhibitor 
U0126 (B) during the priming phase. Analysis was performed as in Fig. 22B. Data are shown as mean 
+ SEM of 8 independent experiments. * P < .05, ** P < .01 determined by repeated measure two-way 




Monocytes and macrophages are exposed to a plethora of stimuli in vivo that eventually 
determines their functional specialization [24]. These cells may be exposed to different and 
sometimes opposing stimuli in a sequential manner, and the priming stimulus may exert a 
significant control over the response to subsequent stimuli, leading to an enhanced activation 
status. The ability of innate immune cells to switch their reactivity in a stimulus specific manner 
and to build up immunological memory is termed “trained immunity” [3]. Trained immunity 
has been reported in several organisms and with a variety of stimuli, including toll like receptor 
(TLR) agonists and endogenous stimuli, such as cytokines [17;26]. Although beneficial in the 
context of resistance against reinfections, this mechanism might be detrimental in non- 
infectious/chronic inflammatory conditions in which myeloid cells contribute to disease 
progression. 
GM-CSF and IL-3 are hematopoietic cytokines that modulate the effector functions of 
several immune cell subsets. In particular, GM-CSF and IL-3 exert a significant control on 
monocyte and macrophage effector functions, and play important roles in maintaining tissue 
homeostasis as well in the pathogenesis of inflammatory and autoimmune disease. Here we 
show that GM-CSF and IL-3 modulate the activation of human CD14+ monocyte in response 
to LPS stimulation in short- and long-term models of trained immunity. Employing a short- 
term model of trained immunity, we demonstrated that GM-CSF and IL-3 priming of human 
monocytes increases TNF-α production in response to LPS stimulation. To understand the 
regulation of TNF-α production in GM-CSF and IL-3 primed monocytes, we looked at 
intracellular TNF-α protein levels, TNF mRNA and primary transcript levels upon LPS 
stimulation for 1 and 4 hours. GM-CSF and IL-3 priming increases TNF-α intracellular protein 
levels as early as after 1 hour of LPS stimulation. Unexpectedly, TNF mRNA and primary 
transcript levels are modestly modified by GM-CSF and IL-3 priming. Although in several 
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experimental models priming of monocytes and macrophages results in chromatin remodeling 
[6-14], our data suggest a post-transcriptional regulation of TNF-α production in primed 
monocytes. Post-transcriptional mechanisms, including modulation of mRNA stability and 
translation [40-42], are increasingly recognized as critical regulators of gene and protein 
expression also in immune cells [9;10;39;43;44]. A central, albeit not exclusive role, in the 
modulation of mRNA translation is played by the MAPKs p38 and ERK1/2 [41]. Indeed, the 
inhibition of p38 and ERK1/2 (only for GM-CSF) during LPS stimulation reduces intracellular 
TNF-α protein levels without significantly modulating TNF RNA levels. In keeping with these 
data, GM-CSF priming increases phosphorylation of both ERK1/2 and p38 upon LPS 
stimulation, while IL-3 priming enhances only p38 phosphorylation. TNF-α protein levels are 
also regulated by metabolic cues. Depletion of the intracellular pool of NAD, inhibits TNF-α 
protein production in response to LPS without modifying TNF mRNA levels, moreover the 
same effect has been observed employing inhibitors of the NAD-dependent histone 
deacetylases sirtuin (SIRT) 1 and 2 [43;44]. Our results demonstrate that inhibition of SIRT2 
during priming reduces intracellular TNF-α protein levels without significantly modulating 
TNF RNA levels. However, it is still unclear how SIRT2 inhibition during the priming phase 
modulates TNF-α protein production. Nevertheless, the phenotype of GM-CSF- and IL-3- 
primed monocytes may be regulated by pathways not investigated in this study. For example, 
several mRNAs encoding immune-regulatory proteins, including TNF-α, have AU-rich 
elements (AREs) in their 3′ untranslated region (UTR) [55] that generally determine mRNA 
instability. AREs serve as binding sites for a number of regulatory proteins that either 
destabilize or stabilize their targets mRNA. Among ARE binding protein Tristetraprolin (TTP, 
ZFP36), a LPS inducible protein, binds to AREs of TNF-α and promotes a rapid mRNA decay 
[56]. Moreover, small regulatory micro (mi)-RNAs represent another system that enhances the 
degradation of several mRNAs encoding important components of signal transduction cascades 
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that are activated during adaptive and innate immune responses [55]. Apart from the molecular 
mechanisms that may also reveal subtle differences in monocyte responsiveness to GM-CSF 
and IL-3 priming, genome-wide approaches aimed at evaluating the translatome or at 
comparing the transcriptome and the proteome may provide critical insights into the modulation 
of LPS-induced monocyte response by GM-CSF and IL-3 priming. 
In order to fully characterize the priming effect of GM-CSF and IL-3, we also employed a 
long-term model of trained immunity. Using this model, it was shown that human monocytes 
primed with β-glucan undergo extensive chromatin remodeling that modulates their response 
to subsequent microbial challenges (e.g. increased TNF-α production upon LPS stimulation) 
[10;13]. Our results demonstrate that GM-CSF and IL-3 priming increases LPS-induced TNF- 
α production in this model, but the mechanism is independent of increased TNF gene expression 
(and likely chromatin remodeling). Instead, GM-CSF and IL-3 priming induces an increase of 
cell number and monocyte renewal, responsible for heightened TNF-α production. Macrophage 
renewal is sustained by a gene network that includes the transcription factor c-Myc and requires 
downregulation of the transcription factor MafB. Our results demonstrate that GM-CSF and IL- 
3 priming induces monocyte renewal by increasing the MYC/MAFB mRNA ratio. In keeping 
with these data, the c-Myc inhibitor 10058 F4 restrained monocyte renewal induced by GM- 
CSF and IL-3 priming. Interestingly, proliferation of monocyte-derived cells (either 
macrophages or dendritic cells) has been observed in several models of inflammation 
[25;49;50]. Although we found similarities as well as differences between GM-CSF and IL-3 
priming in the pathways required for monocyte renewal, it is noteworthy that GM-CSF priming 
induces a greater monocyte expansion than IL-3 priming. The reason for this difference 
probably relies in the constitutive expression of CD116 (the α subunit of GM-CSF receptor) by 
human monocytes [52], while CD123 (the α subunit of IL-3 receptor) expression is inducible 
[38;53]. Nevertheless, bone marrow CD14+ monocytes express CD123 [54], thus it is tempting 
48  
to speculate that IL-3 preferentially acts on bone marrow-resident monocytes, while GM-CSF 
exerts its effect on peripheral blood monocytes. Moreover, since priming with both cytokines 
induces monocyte renewal and priming also affects the biology of hematopoietic precursors 
[25,57-59], it would be interesting to assess whether GM-CSF and IL-3 priming can modulate 
the functions of hematopoietic precursors and their progeny. Further studies are required to 




We characterize the activation of human monocytes in response to the hematopoietic cytokines 
GM-CSF and IL-3 using in vitro models of trained immunity. Our results point to mechanisms 
of GM-CSF and IL-3 priming that are independent of chromatin remodeling, but unexpectedly 
rely on post-transcriptional regulation of TNF-α production and c-Myc-dependent monocyte 
renewal. Given the central role of GM-CSF and IL-3 in inflammatory and autoimmune diseases 
[30-33], our results provide important information to understand mechanisms of monocyte 
activation in such disorders and prompt their investigation in vivo. We also demonstrate that 
GM-CSF and IL-3 activate monocytes through shared as well as distinct pathways. Such 
differences may become even more evident in vivo, since it is conceivable that GM-CSF and 
IL-3 are produced with a different timing and/or act on different target populations (e.g. bone 
marrow vs peripheral cells). Thus, GM-CSF and IL-3 may differentially impact on the immune 
response due to distinct effects at the cellular and the system levels. Understanding such 
complexity is poised to unravel distinct as well as overlapping roles for GM-CSF and IL-3 in 
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